In a statement, Novo Nordisk said the rapprochement between the two companies is "a meaningful win for patients in the US" and will expand access to Ozempic and Wegovy, adding that the two products have been "evaluated for safety and efficacy." The company also said that it "welcomes Hims & Hers shifting their GLP-1 business model to focus on increasing access to affordable, branded FDA-approved medicines." It has also agreed to drop its lawsuit with Hims & Hers that followed the compounded oral semaglutide announcement
It is important to evaluate the risks and benefits of common supplemental amino acids, including L-carnitine, L-arginine, and glutamine, particularly concerning kidney function
BoehnkeCReuterUFlachUSchuh-HoferSEinhuplKArnoldG
doi: 10.3390/antibiotics12071157 251 UthamanSKKangWSParkJYKimSLeDDOhSJet al
Focus on oats, barley, lentils, chickpeas, broccoli, and leafy greens
SNAC alone did not affect the AUC or C max of ethinylestradiol, levonorgestrel or rosuvastatin